Bio-Key Intl Inc Financials
Bio-Key Intl Inc (BKYI) reported $5.9M in revenue for fiscal year 2025, down 14.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
GAAP profit is not funding the business; recurring operating cash burn still requires outside capital to maintain liquidity.
Across FY2023-FY2025, net income stayed positive, ranging from$4.3M to$8.5M . But cash earning power moved the other way: operating cash flow stayed negative between-$2.9M and-$4.7M , while operating income was negative each year, implying items below the operating line are shaping reported profit more than the core business.
The core constraint is cost structure versus sales scale, not product gross economics alone. In FY2025, SG&A plus R&D totaled
This is a low-capex business: FY2025 capital spending was only
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Bio-Key Intl Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Bio-Key Intl Inc's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 26/100.
Bio-Key Intl Inc's revenue declined 14.3% year-over-year, from $6.9M to $5.9M. This contraction results in a growth score of 9/100.
Bio-Key Intl Inc has a moderate D/E ratio of 0.63. This balance of debt and equity financing earns a leverage score of 55/100.
Bio-Key Intl Inc's current ratio of 1.47 indicates adequate short-term liquidity, earning a score of 39/100. The company can meet its near-term obligations, though with limited headroom.
Bio-Key Intl Inc's operations used $4.7M of cash, and capex of $12K added to the outflow, for a free cash flow shortfall of $4.7M. This results in a cash flow score of 8/100.
Bio-Key Intl Inc generates a 140.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 11/100. This is up from 114.0% the prior year.
Bio-Key Intl Inc scores -23.99, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($4.3M) relative to total liabilities ($3.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Bio-Key Intl Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Bio-Key Intl Inc used $0.65 of operating cash (-$4.7M OCF vs $7.2M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Bio-Key Intl Inc reported an operating loss of $6.8M against $61K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Bio-Key Intl Inc generated $5.9M in revenue in fiscal year 2025. This represents a decrease of 14.3% from the prior year.
Bio-Key Intl Inc's EBITDA was -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 72.1% from the prior year.
Bio-Key Intl Inc reported $7.2M in net income in fiscal year 2025. This represents an increase of 66.4% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Bio-Key Intl Inc recorded an outflow of $4.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 59.9% from the prior year.
Bio-Key Intl Inc held $2.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Bio-Key Intl Inc's gross margin was 76.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 4.5 percentage points from the prior year.
Bio-Key Intl Inc's ROE was 140.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 26.1 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Bio-Key Intl Inc invested $2.6M in research and development in fiscal year 2025. This represents an increase of 3.9% from the prior year.
Bio-Key Intl Inc invested $12K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 7.9% from the prior year.
Not reported for fiscal year 2025.
BKYI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.7M | $5.9M-14.3% | $6.9M-10.6% | $7.8M+10.5% | $7.0M+37.3% | $5.1M+80.3% | $2.8M+25.1% | $2.3M-43.9% | $4.0M-35.8% | $6.3M+111.8% | $3.0M-43.4% | $5.3M+31.3% | $4.0M+101.7% | $2.0M-48.2% | $3.8M+9.3% | $3.5M |
| Cost of Revenue | $1.3M | $1.4M+6.5% | $1.3M-79.6% | $6.3M+159.2% | $2.4M+45.8% | $1.7M+110.5% | $795K-67.7% | $2.5M-40.9% | $4.2M+28.4% | $3.2M+344.3% | $730K-43.0% | $1.3M+70.9% | $749K+93.5% | $387K-32.3% | $572K-29.5% | $810K |
| Gross Profit | $5.4M | $4.6M-19.1% | $5.6M+294.1% | $1.4M-68.8% | $4.6M+33.1% | $3.4M+68.5% | $2.0M+1154.1% | -$194K-61.9% | -$120K-103.9% | $3.1M+36.3% | $2.2M-43.6% | $4.0M+22.2% | $3.3M+103.7% | $1.6M-51.0% | $3.3M+21.0% | $2.7M |
| R&D Expenses | $2.6M | $2.6M+3.9% | $2.5M+4.9% | $2.4M-26.4% | $3.3M+38.1% | $2.4M+68.6% | $1.4M+4.9% | $1.3M-5.9% | $1.4M-14.7% | $1.7M-17.4% | $2.0M+29.1% | $1.6M-4.3% | $1.6M+21.0% | $1.3M+41.9% | $947K-15.2% | $1.1M |
| SG&A Expenses | $6.1M | $6.3M-12.0% | $7.1M-9.2% | $7.9M-16.0% | $9.4M+55.3% | $6.0M+3.1% | $5.8M+16.1% | $5.0M-5.6% | $5.3M-6.0% | $5.7M+27.9% | $4.4M+7.7% | $4.1M+12.3% | $3.7M+32.2% | $2.8M+21.3% | $2.3M-24.6% | $3.0M |
| Operating Income | -$5.8M | -$6.8M-70.2% | -$4.0M+54.6% | -$8.8M+11.1% | -$9.9M-100.8% | -$4.9M+5.0% | -$5.2M-386.7% | -$1.1M-1336325.0% | $80+100.0% | -$4.3M-1.8% | -$4.2M-147.7% | -$1.7M+16.8% | -$2.0M+19.1% | -$2.5M-9142.8% | $28K+101.9% | -$1.5M |
| Interest Expense | $53K | $61K-65.4% | $176K-19.5% | $218K+1986.3% | $10K-41.9% | $18K-99.6% | $4.3M+306.2% | $1.1M+1336317.5% | $80+196.3% | $27-10.0% | $30-100.0% | $192K+2745600.0% | $7-100.0% | $136K+454.2% | $25K-94.0% | $412K |
| Income Tax | $17K | $17K+171.7% | -$23K+82.8% | -$134K-555.8% | -$20K | $0 | $0 | $0 | $0 | $0+100.0% | -$12K-107.5% | $161K+9306.7% | $2K-39.0% | $3K | N/A | $27K |
| Net Income | $8.3M | $7.2M+66.4% | $4.3M-49.5% | $8.5M+171.6% | -$11.9M-135.1% | -$5.1M+47.6% | -$9.7M | N/A | -$6.9M-60.7% | -$4.3M-2.0% | -$4.2M-125.6% | -$1.9M+1.4% | -$1.9M+27.1% | -$2.6M-79137.4% | $3K+100.2% | -$1.9M |
Not reported in any period shown, so not listed: EPS (Diluted).
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BKYI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.3M-3.6% | $8.6M+90.7% | $4.5M-60.2% | $11.3M-36.2% | $17.8M-21.1% | $22.5M+802.0% | $2.5M-78.6% | $11.7M-27.3% | $16.1M-7.0% | $17.3M-15.3% | $20.4M+887.5% | $2.1M-23.5% | $2.7M+137.6% | $1.1M+17.6% | $967K |
| Current Assets | $4.5M+140.5% | $1.9M-28.0% | $2.6M-70.8% | $9.0M-35.9% | $14.0M-26.0% | $18.9M+1286.4% | $1.4M-67.7% | $4.2M-39.7% | $7.0M+42.8% | $4.9M-62.3% | $13.0M+625.6% | $1.8M-25.0% | $2.4M+163.5% | $908K+30.1% | $698K |
| Cash & Equivalents | $2.7M+515.8% | $438K-14.4% | $511K-80.6% | $2.6M-66.0% | $7.8M-54.4% | $17.0M+21406.7% | $79K-75.6% | $324K+12.2% | $289K-72.8% | $1.1M-75.4% | $4.3M+412.2% | $844K-58.3% | $2.0M+2309.1% | $84K+93.4% | $43K |
| Inventory | $371K-2.0% | $378K-15.1% | $446K-89.9% | $4.4M-10.2% | $4.9M+1392.9% | $331K-22.9% | $429K-57.0% | $999K+5.5% | $947K+103.4% | $465K+176.0% | $169K+1326.2% | $12K+26.1% | $9K+124.0% | $4K-49.2% | $8K |
| Accounts Receivable | $1.2M+70.0% | $718K-40.2% | $1.2M-21.1% | $1.5M+56.9% | $971K+77.1% | $548K+335.0% | $126K-92.0% | $1.6M-45.3% | $2.9M+84.0% | $1.6M-53.9% | $3.4M+442.3% | $625K+120.2% | $284K-53.0% | $605K+3.0% | $587K |
| Goodwill | N/A | N/A | N/A | $0-100.0% | $1.3M0.0% | $1.3M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.2M-34.0% | $4.8M+40.3% | $3.5M-42.8% | $6.0M+180.6% | $2.2M-1.5% | $2.2M-54.3% | $4.8M+290.0% | $1.2M-47.3% | $2.3M+26.6% | $1.8M-19.0% | $2.3M+73.2% | $1.3M-20.7% | $1.7M-29.9% | $2.4M+5.2% | $2.2M |
| Current Liabilities | $3.1M-32.0% | $4.6M+41.7% | $3.2M-41.1% | $5.5M+172.9% | $2.0M+6.6% | $1.9M-57.3% | $4.4M+258.2% | $1.2M-47.3% | $2.3M+26.6% | $1.8M-19.0% | $2.3M+73.2% | $1.3M-7.0% | $1.4M-40.2% | $2.4M+5.3% | $2.2M |
| Long-Term Debt | N/A | $45K-76.3% | $189K-42.2% | $327K | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $5.1M+35.4% | $3.8M+254.7% | $1.1M-79.9% | $5.3M-66.0% | $15.6M-23.2% | $20.3M+989.9% | -$2.3M-121.8% | $10.5M-23.9% | $13.8M-11.0% | $15.5M-14.9% | $18.1M+2291.1% | $759K-27.8% | $1.1M+186.3% | -$1.2M+4.2% | -$1.3M |
| Retained Earnings | -$136.5M-5.5% | -$129.3M-3.4% | -$125.0M-7.3% | -$116.5M-11.4% | -$104.6M-5.1% | -$99.5M-10.9% | -$89.7M-19.4% | -$75.1M-12.0% | -$67.1M-6.8% | -$62.8M-7.1% | -$58.6M-3.3% | -$56.8M-3.4% | -$54.9M-4.9% | -$52.3M0.0% | -$52.3M |
BKYI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.2M | -$4.7M-60.2% | -$2.9M+23.2% | -$3.8M+39.1% | -$6.2M+30.6% | -$9.0M-81.4% | -$5.0M-167.5% | -$1.9M-14.7% | -$1.6M+34.6% | -$2.5M+44.6% | -$4.4M+71.4% | -$15.6M-521.7% | -$2.5M+6.7% | -$2.7M-4194.3% | $66K+112.5% | -$523K |
| Capital Expenditures | $6K | $12K-7.9% | $13K+1204.7% | $1K-98.8% | $82K+95.2% | $42K+18.2% | $36K+23.7% | $29K-44.8% | $52K-68.6% | $166K+213.5% | $53K+1474.8% | $3K-81.9% | $19K-85.6% | $129K | N/A | $56K |
| Free Cash Flow | -$4.2M | -$4.7M-59.9% | -$2.9M+22.9% | -$3.8M+39.9% | -$6.3M+30.0% | -$9.0M-80.9% | -$5.0M-165.3% | -$1.9M-12.8% | -$1.7M+36.7% | -$2.6M+41.5% | -$4.5M+71.1% | -$15.6M-517.2% | -$2.5M+10.4% | -$2.8M | N/A | -$579K |
| Investing Cash Flow | -$6K | -$12K+7.9% | -$13K-1204.7% | -$1K+99.9% | -$697K-1557.7% | -$42K+98.1% | -$2.2M-310.4% | -$543K-558.9% | -$82K+63.6% | -$227K-328.0% | -$53K-1474.8% | -$3K+81.9% | -$19K+85.6% | -$129K | N/A | $3.3M |
| Financing Cash Flow | $3.4M | $6.9M+144.5% | $2.8M+97.2% | $1.4M-24.7% | $1.9M+970.7% | -$219K-100.9% | $24.1M+1021.3% | $2.1M+24.1% | $1.7M-9.8% | $1.9M+54.8% | $1.2M-93.5% | $19.0M+1319.0% | $1.3M-71.8% | $4.8M+19110.7% | -$25K+99.3% | -$3.7M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
BKYI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.9%-4.5pp | 81.4%+62.9pp | 18.5%-46.8pp | 65.3%-2.0pp | 67.3%-4.7pp | 72.0%+80.5pp | -8.5%-5.6pp | -3.0%-51.5pp | 48.6%-26.9pp | 75.5%-0.2pp | 75.7%-5.6pp | 81.3%+0.8pp | 80.5%-4.6pp | 85.1%+8.2pp | 76.9% |
| Operating Margin | -115.0% | -57.9% | -113.8% | -141.4% | -96.6% | -183.4% | -47.1%-47.1pp | 0.0%+67.8pp | -67.8% | -141.2% | -32.2%+18.7pp | -50.9% | -127.0% | 0.7%+42.2pp | -41.5% |
| Net Margin | 120.5% | 62.1% | 109.9% | -169.6% | -99.1% | -341.0% | N/A | -169.8% | -67.8% | -140.8% | -35.3%+11.7pp | -47.0% | -130.0% | 0.1%+54.2pp | -54.1% |
| Return on Equity | 140.2%+26.1pp | 114.0%-687.2pp | 801.2%+1025.9pp | -224.7%-192.2pp | -32.4%+15.1pp | -47.6% | N/A | -65.6%-34.5pp | -31.1%-4.0pp | -27.1%-16.9pp | -10.2%+237.9pp | -248.2%-2.5pp | -245.7% | N/A | N/A |
| Return on Assets | 86.2%+36.3pp | 49.9%-138.7pp | 188.7%+293.7pp | -105.0%-76.5pp | -28.5%+14.4pp | -43.0% | N/A | -58.8%-32.2pp | -26.6%-2.4pp | -24.2%-15.1pp | -9.1%+82.0pp | -91.1%+4.5pp | -95.6%-95.9pp | 0.3%+196.6pp | -196.3% |
| Current Ratio | 1.47+1.1x | 0.41-0.4x | 0.82-0.8x | 1.65-5.4x | 7.01-3.1x | 10.10+9.8x | 0.31-3.1x | 3.45+0.4x | 3.02+0.3x | 2.67-3.1x | 5.74+4.4x | 1.37-0.3x | 1.70+1.3x | 0.39+0.1x | 0.31 |
| Debt-to-Equity | 0.63+0.6x | 0.01-0.2x | 0.18+0.1x | 0.06+0.1x | 0.00-0.1x | 0.11 | N/A | 0.12-0.1x | 0.17+0.1x | 0.120.0x | 0.12-1.6x | 1.72+0.2x | 1.57 | N/A | N/A |
| FCF Margin | -78.8%-36.6pp | -42.2%+6.7pp | -48.9%+41.0pp | -89.9% | -176.4% | -175.8% | -82.9%-41.7pp | -41.2%+0.6pp | -41.8% | -151.2% | -295.8% | -62.9% | -141.7% | N/A | -16.5% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Bio-Key Intl Inc Ranks
Frequently Asked Questions
What is Bio-Key Intl Inc's annual revenue?
Bio-Key Intl Inc (BKYI) reported $5.9M in total revenue for fiscal year 2025. This represents a -14.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bio-Key Intl Inc's revenue growing?
Bio-Key Intl Inc (BKYI) revenue declined by 14.3% year-over-year, from $6.9M to $5.9M in fiscal year 2025.
Is Bio-Key Intl Inc profitable?
Yes, Bio-Key Intl Inc (BKYI) reported a net income of $7.2M in fiscal year 2025.
What is Bio-Key Intl Inc's EBITDA?
Bio-Key Intl Inc (BKYI) had EBITDA of -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Bio-Key Intl Inc's gross margin?
Bio-Key Intl Inc (BKYI) had a gross margin of 76.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bio-Key Intl Inc's return on equity (ROE)?
Bio-Key Intl Inc (BKYI) has a return on equity of 140.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bio-Key Intl Inc's free cash flow?
Bio-Key Intl Inc (BKYI) recorded an outflow of $4.7M in free cash flow during fiscal year 2025. This represents a -59.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bio-Key Intl Inc's operating cash flow?
Bio-Key Intl Inc (BKYI) recorded an outflow of $4.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Bio-Key Intl Inc's total assets?
Bio-Key Intl Inc (BKYI) had $8.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Bio-Key Intl Inc's capital expenditures?
Bio-Key Intl Inc (BKYI) invested $12K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Bio-Key Intl Inc spend on research and development?
Bio-Key Intl Inc (BKYI) invested $2.6M in research and development during fiscal year 2025.
What is Bio-Key Intl Inc's current ratio?
Bio-Key Intl Inc (BKYI) had a current ratio of 1.47 as of fiscal year 2025, which is considered adequate.
What is Bio-Key Intl Inc's debt-to-equity ratio?
Bio-Key Intl Inc (BKYI) had a debt-to-equity ratio of 0.63 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bio-Key Intl Inc's return on assets (ROA)?
Bio-Key Intl Inc (BKYI) had a return on assets of 86.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bio-Key Intl Inc's cash runway?
Based on fiscal year 2025 data, Bio-Key Intl Inc (BKYI) had $2.7M in cash against an annual operating cash burn of $4.7M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Bio-Key Intl Inc's Altman Z-Score?
Bio-Key Intl Inc (BKYI) has an Altman Z-Score of -23.99, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Bio-Key Intl Inc's Piotroski F-Score?
Bio-Key Intl Inc (BKYI) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bio-Key Intl Inc's earnings high quality?
For every $1 of reported earnings, Bio-Key Intl Inc (BKYI) used $0.65 of operating cash (-$4.7M OCF vs $7.2M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Bio-Key Intl Inc cover its interest payments?
Bio-Key Intl Inc (BKYI) reported an operating loss of $6.8M against $61K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Bio-Key Intl Inc?
Bio-Key Intl Inc (BKYI) scores 25 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.